Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) (TA242)
Fast, easy summary view of NICE guidance on 'colorectal cancer'
Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of TA150 and part review of TA118)
NICE does not recommend cetuximab (on its own or in combination with chemotherapy) for people with metastatic colorectal cancer that has progressed (worsened) after first-line (first course) chemotherapy.
NICE does not recommend bevacizumab in combination with a fluoropyrimidine-based chemotherapy regimen for people with metastatic colorectal cancer that has progressed after first-line chemotherapy.
NICE does not recommend panitumumab on its own for people with metastatic colorectal cancer that has progressed after first-line chemotherapy.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
Cetuximab does not provide enough benefit to patients to justify its high cost and did not qualify for special consideration.
There was no evidence available to assess whether bevacizumab in combination with a fluoropyrimidine-based chemotherapy regimen works for people with metastatic colorectal cancer that has worsened after first-line chemotherapy, so NICE could not recommend it.
Panitumumab does not provide enough benefit to patients to justify its high cost even when the special considerations were applied.
- TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: colorectal cancer
- None found
This page was last updated: 25 September 2012
- Web format
- Full Guidance (PDF)
- TA242 Cetuximab, bevacizumab a phanitumumab ar gyfer canser metastatig y colon a'r rhefr ar ôl cemotherapi llinell flaen: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.